Lipella Doses First Patient in Human Clinical Study of Contrast Agent

Clinical stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO), has dosed the first patient in its human clinical study of an innovative MRI contrast agent.

The agent is expected to be useful for the diagnosis of interstitial cystitis/bladder pain syndrome (IC/BPS) and potentially other bladder diseases characterized by bladder wall defects.


  •  Lipella’s contrast agent is composed of two MRI contrast agents and is expected to demonstrate accuracy in measuring impaired bladder permeability and function.
  • The company believes the agent may be useful in diagnosing a number of bladder diseases and may also have utility in detecting bladder tumor progression to muscle-invasive bladder cancer.
  • The study is being funded by a $1.35 million Small Business Innovation Research (SBIR) Phase II grant awarded to Lipella by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in 2022.
  • The two-year grant will support the clinical development of intravesical contrast-enhanced magnetic resonance imaging (ICE-MRI) technology.
  • The agent has the potential to identify patients who would be most likely to benefit from clinical trials of newer therapies targeting bladder pathology and avoid delays in getting appropriate medical care.

 About Lipella Pharmaceuticals

Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, Lipella maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella completed its initial public offering in December 2022. For more information, please visit or LinkedIn.


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

Lipella Doses First Patient in Human Clinical Study of Contrast Agent

Editor Prism MarketView